BTK inhibitor | Indication: FDA approval | Indication: China approval |
---|---|---|
Ibrutinib | CLL/SLL, WM, R/R MZL, R/R MCL | China: CLL/SLL, R/R MCL, WM Hong Kong: CLL/SLL, R/R MCL, WM Taiwan: CLL/SLL, R/R MCL, WM, R/R MZL |
Acalabrutinib | CLL/SLL, R/R MCL | China: R/R MCL; R/R CLL/SLL Hong Kong: CLL/SLL, R/R MCL Taiwan: CLL/SLL, R/R MCL |
Zanubrutinib | CLL/SLL, WM, R/R MCL, R/R MZL | China: CLL/SLL, WM, R/R MCL Hong Kong: CLL/SLL, WM, R/R MCL Taiwan: CLL/SLL, WM, R/R MCL, R/R MZL |
Orelabrutinib | None | China: R/R MCL, R/R CLL, R/R MZL |
Tirabrutinib | R/R PCNSL | Taiwan: R/R PCNSL |
Pirtobrutinib | R/R MCL | None |